2,731 Shares in Biogen Inc. $BIIB Acquired by Waterfront Wealth Inc.

Waterfront Wealth Inc. acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,731 shares of the biotechnology company’s stock, valued at approximately $402,000.

A number of other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC boosted its stake in shares of Biogen by 210.9% in the third quarter. Smartleaf Asset Management LLC now owns 628 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 426 shares during the period. Alps Advisors Inc. lifted its holdings in Biogen by 24.2% in the 3rd quarter. Alps Advisors Inc. now owns 3,143 shares of the biotechnology company’s stock worth $440,000 after buying an additional 612 shares in the last quarter. MMA Asset Management LLC purchased a new position in Biogen in the 3rd quarter valued at about $84,000. Prasad Wealth Partners LLC purchased a new position in Biogen in the 3rd quarter valued at about $203,000. Finally, Sentry Investment Management LLC acquired a new stake in shares of Biogen during the third quarter valued at about $46,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 748 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the sale, the insider directly owned 6,271 shares in the company, valued at approximately $1,124,390.30. This trade represents a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.18% of the stock is owned by corporate insiders.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $193.81 on Tuesday. The company has a market cap of $28.43 billion, a PE ratio of 22.00, a P/E/G ratio of 1.70 and a beta of 0.16. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The firm has a 50-day simple moving average of $177.26 and a 200 day simple moving average of $157.48. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Analyst Ratings Changes

BIIB has been the topic of several analyst reports. Wall Street Zen downgraded Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Royal Bank Of Canada upped their price target on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a report on Monday. Wolfe Research set a $231.00 price objective on shares of Biogen in a report on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Finally, TD Cowen increased their price target on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday. Thirteen investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $206.21.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.